Half-Year 2022 Financial Performance

Capsules & Health Ingredients (CHI) Financial and operational performance in H1 2022 Lonza 625m Sales (CHF) 220m CORE EBITDA (CHF) 35.2% CORE EBITDA Margin +4.0%¹ +3.3% -0.2ppts - ― Continued momentum driven by specialty capsules - Expansion of capsule offering to include titanium dioxide-free white hard gelatin capsules compliant with European regulation On track to deliver 260bn annualized capsule capacity by year-end Robust margin compared to H1 2021 as pricing strategy contributes to offset inflationary pressures Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) CORE definition: See appendix 22 22

View entire presentation